Kontrast Madde Nefropatisi: Antioksidan Tedavi Yönetimi

Yıl 2017, Cilt: 20 Sayı: 1, 59 - 62, 03.04.2017

Mutlu Büyüklü Eftal Murat Bakırcı Hüsnü Değirmenci Gökhan Ceyhun Ergün Topal

Öz

Günümüzde
görüntüleme ve girişimsel işlemlerin artış göstermesi ile birlikte kontrast
madde kullanımı  giderek artmıştır.
Oksidatif stresin kontrast madde nefropatisi patofizyolojisinde önemli rolü
vardır. Çeşitli önleyici tedaviler ve yan etkisi daha az düşük osmolar kontrast
maddelere rağmen, klinik pratikte tek önleyici tedavi intravenöz iztonik
infüzyonudur. Bu yüzden yeni bir koruyucu tedaviye ihtiyaç vardır.

Anahtar Kelimeler

Kontrast, kontrast madde nefropatisi, antioksidan tedavi, anjiyografi

Contrast-Induced Nephropathy: Management by Antioxidant Therapy

Öz

At
present, the number of imaging and interventional procedures using contrast
agents is gradually increasing. Oxidative stress plays a significant role in
its pathophysiology. Despite the use of various prophylactic therapies and
low-osmolar contrast agents with lesser adverse effects, intravenous isotonic
fluid infusion is the only method that has been proven to be effective in
preventing contrast-induced nephropathy in clinic practice. Therefore, a novel
kidney-protecting treatment model is required for contrast-induced nephropathy.

Anahtar Kelimeler

Contrast, contrast-induced nephropathy, antioxidant treatment, angiography

Kaynakça

• 1. Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004;44:12-24.
• 2. Wong PC, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. Int J Cardiol 2012;158:186-92.
• 3. Persson PB. Contrast-induced nephropathy. Eur Radiol Suppl 2005;4:65-9.
• 4. Ozkan G, Ulusoy S, Orem A, Ersoz S, Alkanat M, Yucesan FB, et al. Protective effect of the grape seed proanthocyanidin extract in a rat model of contrast-induced nephropathy. Kidney Blood Press Res 2012;35:445-53.
• 5. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
• 6. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007;5:32.
• 7. Spargias K, Alexopoulos E, Kyrzopoulos S, Iokovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837-42.
• 8. Boscheri A, Weinbrenner C, Botzek B, Reynen K, Kuhlisch E, Strasser RH. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol 2007;68:279-86.
• 9. Jo SH, Koo BK, Park JS, Kang HJ, Kim YJ, Kim HL, et al. N-acetylcysteine versus ascorbic acid for preventing contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J 2009;157:576-83.
• 10. Zhou L, Chen H. Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med 2012;51:531-5.
• 11. Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic Acid. Front Pharmacol 2011;2:69.
• 12. Jo SH, Kim SA, Kim HS, Han SJ, Park WJ, Choi YJ. Alpha-lipoic acid for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography: the ALIVE study - a prospective randomized trial. Cardiology 2013;126:159-66.
• 13. Cicek M, Yıldırır A, Okyay K, Yazici AC, Aydinalp A, Kanyilmaz S, et al. Use of alpha-lipoic acid in prevention of contrast-induced nephropathy in diabetic patients. Ren Fail 2013;35:748-53.
• 14. Kongkham S, Sriwong S, Tasanarong A. Protective effect of alpha tocopherol on contrast-induced nephropathy in rats. Nefrologia 2013;33:116-23.
• 15. Tasanarong A, Vohakiat A, Hutayanon P, Piyayotai D. New strategy of α- and γ-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. Nephrol Dial Transplant 2013;28:337-44.
• 16. Tan SM, Sharma A, Yuen DY, Stefanovic N, Krippner G, Mugesh G, et al. The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy and diabetes-associated atherosclerosis in ApoE/GPx1 double knockout mice. PLoS One 2013;8:69193.
• 17. Ozgur T, Tutanc M, Zararsiz I, Motor S, Ozturk OH, Yaldiz M, et al. The protective effect of ebselen on radiocontrast-induced nephrotoxicity. Ren Fail 2012;34:991-7.
• 18. Izquierdo MJ, Cavia M, Muñiz P, de Francisco AL, Arias M, Santos J, et al. Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrol 2012;13:159.
• 19. Ari E, Kedrah AE, Alahdab Y, Bulut G, Eren Z, Baytekin O, et al. Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. Br J Radiol 2012;85:1038-43.
• 20. Mansouri E, Panahi M, Ghaffari MA, Ghorbani A. Effects of grape seed proanthocyanidin extract on oxidative stress induced by diabetes in rat kidney. Iran Biomed J 2011;15:100-6.
• 21. Stefanska J, Pawliczak R. Apocynin: molecular aptitudes. Mediators Inflamm 2008;2008:106507.
• 22. Ahmad A, Mondello S, Di Paola R, Mazzon E, Esposito E, Catania MA, et al. Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. Eur J Pharmacol 2012;674:397-406.
• 23. Alp H, Varol S, Celik MM, Altas M, Evliyaoglu O, Tokgoz O, et al. Protective effects of beta glucan and gliclazide on brain tissue and sciatic nerve of diabetic rats induced bystreptozosin. Exp Diabetes Res 2012;2012:230342.
• 24. Koc E, Reis KA, Ebinc FA, Pasaoglu H, Demirtas C, Omeroglu S, et al. Protective effect of beta-glucan on contrast induced-nephropathy and a comparison of beta-glucan with nebivolol and N-acetylcysteine in rats. Clin Exp Nephrol 2011;15:658-65.
• 25. Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008;23:853-9.
• 26. Avci E, Yeşil M, Bayata S, Postaci N, Arikan E, Cirit M. The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction. Anadolu Kardiyol Derg 2011;11:613-7.
• 27. Günebakmaz O, Kaya MG, Koc F, Akpek M, Kasapkara A, Inanc MT, et al. Does nebivolol prevent contrast-induced nephropathy in humans? Clin Cardiol 2012; 35:250-4.
• 28. Hsu DZ, Li YH, Chu PY, Periasamy S, Liu MY. Sesame oil prevents acute kidney injury induced by the synergistic action of aminoglycoside and iodinated contrast in rats. Antimicrob Agents Chemother 2011;55:2532-6.
• 29. Lee HC, Sheu SH, Liu IH, Lee CC, Hsieh CC, Yen HW, et al. Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. J Nephrol 2012;25:56-62.
• 30. Li G, Yin L, Liu T, Zheng X, Xu G, Xu Y, et al. Role of probucol in preventing contrast-induced acute kidney injury after coronary interventional procedure. Am J Cardiol 2009;103:512-4.
• 31. Yıldız M. Intensive care, heart failure and melatonin. Kosuyolu Heart J 2007;11:11-2.
• 32. Gazi S, Altun A, Erdogan O. Contrast-induced nephropathy: preventive and protective effects of melatonin. J Pineal Res 2006;41:53-7.
• 33. Duan BJ, Huang L, Ding H, Huang WY. [Curcumin attenuates contrast-induced nephropathy by upregulating heme oxygenase-1 expression in rat]. Zhonghua Xin Xue Guan Bing Za Zhi 2013;41:116-20.
• 34. Buyuklu M, Kandemir FM, Ozkaraca M, Set T, Bakirci EM, Topal E. Protective effect of curcumin against contrast induced nephropathy in rat kidney: what is happening to oxidative stress, inflammation, autophagy and apoptosis? Eur Rev Med Pharmacol Sci 2014;18:461-70.
• 35. Onbasili AO, Yeniceriglu Y, Agaoglu P, Karul A, Tekten T, Akar H, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007;93:698-702.
• 36. Rahman MM, Haque SS, Rokeya B, Siddique MA, Banerjee SK, Ahsan SA, et al. Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram. Mymensingh Med J 2012;21:292-9.
• 37. Akgüllü C, Saruhan T, Eryilmaz U, Boyacıoğlu M, Onbaşılı OA, Meteoğlu I, et al. The first histopathological evidence of trimetazidine for the prevention of contrast-induced nephropathy. Ren Fail 2014;28.